ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Droplet Squeeze Microfluidic Platform for Generating Extracellular Vesicle Hybrids for Drug Delivery.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Beyond Exosomes: Biological Properties, Isolation Challenges, and Functional Redefinition of Non-Vesicular Extracellular Nanoparticles (NVEPs).Biomolecules · 2026Review
- Parallelized droplet microfluidic mechanoporation enables robust and clogging-resistant intracellular gene delivery.Microsystems & nanoengineering · 2026Article
- Exercise-derived extracellular vesicles in oncology: a new frontier for translational nanomedicine.Journal of translational medicine · 2026Review
- The role and prospects of extracellular vesicles in advanced drug and vaccine delivery.Frontiers in immunology · 2026Review
- Inhalable extracellular vesicles as cell-free therapeutics for chronic respiratory disease.Frontiers in bioengineering and biotechnology · 2026Review
- Droplet Squeeze Microfluidic Platform for Generating Extracellular Vesicle Hybrids for Drug Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Extracellular vesicles (EVs) are emerging as versatile drug delivery systems due to their intrinsic biocompatibility and targeting capabilities. However, EV integrity and efficient drug loading challenges hinder their clinical translation. To address these limitations, hybrid systems integrating lipid nanoparticles (LNPs) with EVs have gained attention for their potential in targeted and combinatorial drug delivery. This study presents a robust microfluidic approach for the scalable generation of drug-loaded EV-LNP hybrids (EV hybrids). The method facilitates controlled fusion between EVs and LNPs by utilizing a droplet-mediated squeezing mechanism. Lipid composition and microfluidic parameters are optimized for the fusion of EVs and LNPs and determined physicochemical and functional characterizations of the EV hybrids. In vitro studies demonstrate that EV hybrids exhibit enhanced targeting efficiency. Moreover, small-molecule therapeutics are successfully encapsulated within EV hybrids, significantly improving cytotoxic efficacy against melanoma in 2D and 3D culture models compared to drug-loaded EVs or LNPs alone. The work introduces a scalable, minimally disruptive microfluidic platform for engineering EV hybrids, offering a promising strategy to advance precision nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.